Base title: prevent preclinical drug development program: preclinical efficacy and intermediate endpoint biomarkers task order title: colorectal cancer (CRC) prevention by tpst-1495 in pirc RAT model
Active Awarded Last action
- Contract number
- 75N91023F00001
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,140,397
Award facts
- Contract value 100% obligated
- $1,140,397.00 Current and potential, with all options
- Completion date 78% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73104, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $1,140,397 |
About this award
The National Cancer Institute issued a delivery order to the University of Oklahoma Health Sciences Center on September 11, 2023, with a ceiling value of $1,140,397, for preclinical efficacy testing of the candidate drug TPST-1495 in a colorectal cancer prevention model using PIRC rats, under the PREVENT Preclinical Drug Development Program IDIQ.
Place of performance is Oklahoma City, OK. The order is firm fixed price with an ultimate completion date of September 10, 2027. No set-aside was used.
In fiscal year 2024, the order invoiced $283 thousand across 2.4 FTEs and 5,015 contractor hours, yielding a derived government-paid hourly rate of $56.51. The prime self-performed all reported work with no subcontractors.
Quick answers
Who was awarded contract 75N91023F00001?
75N91023F00001 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on September 11, 2023.
How much is contract 75N91023F00001 worth?
The government has obligated $1,140,397 on 75N91023F00001.
Is contract 75N91023F00001 an order under another contract?
Yes. 75N91023F00001 is a delivery order under 75N91019D00020, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91023F00001 competed?
The extent of competition for 75N91023F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award